326 related articles for article (PubMed ID: 30008698)
1. Neuropeptide G Protein-Coupled Receptors as Oncotargets.
Moody TW; Ramos-Alvarez I; Jensen RT
Front Endocrinol (Lausanne); 2018; 9():345. PubMed ID: 30008698
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptides as autocrine growth factors in cancer cells.
Moody TW; Chan D; Fahrenkrug J; Jensen RT
Curr Pharm Des; 2003; 9(6):495-509. PubMed ID: 12570813
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptors as cancer drug targets.
Moody TW
Ann N Y Acad Sci; 2019 Nov; 1455(1):141-148. PubMed ID: 31074514
[TBL] [Abstract][Full Text] [Related]
4. Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases.
Moody TW; Ramos-Alvarez I; Jensen RT
Peptides; 2021 Mar; 137():170480. PubMed ID: 33385499
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.
Arimura A
Jpn J Physiol; 1998 Oct; 48(5):301-31. PubMed ID: 9852340
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats.
Läuffer JM; Modlin IM; Hinoue T; Kidd M; Zhang T; Schmid SW; Tang LH
Gastroenterology; 1999 Mar; 116(3):623-35. PubMed ID: 10029621
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
12. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase.
Lelièvre V; Pineau N; Du J; Wen CH; Nguyen T; Janet T; Muller JM; Waschek JA
J Biol Chem; 1998 Jul; 273(31):19685-90. PubMed ID: 9677397
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
Moody TW; Zia F; Makheja A
Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
[TBL] [Abstract][Full Text] [Related]
16. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H
Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
Harmar AJ; Fahrenkrug J; Gozes I; Laburthe M; May V; Pisegna JR; Vaudry D; Vaudry H; Waschek JA; Said SI
Br J Pharmacol; 2012 May; 166(1):4-17. PubMed ID: 22289055
[TBL] [Abstract][Full Text] [Related]
19. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
